為何選擇 GALEAS™ Bladder?

超靈敏檢測

檢測出現於超過 96% 膀胱癌病例中的 23 個基因的體細胞突變

非侵入性

簡單的尿液檢測，無需進行膀胱鏡檢查等侵入性程序

已廣泛應用於研究隊列

在英國三個臨床隊列中，對 710 份尿液樣本進行測試，確保高精度和可靠性

全面報告

提供詳細的體細胞變異分析及陽性/陰性結果

Watch the GALEAS™ Bladder Video Introduction

GALEAS™ Bladder 性能數據

GALEAS™ Bladder 在膀胱癌的各個分期和分級中表現卓越：

	Sensitivity	Specificity	NPV
pTa	89%	86%	99%
T1	97%	86%	99%
T2+	92%	86%	99%
G1	78%	86%	99%
G2	93%	86%	99%
G3	96%	86%	99%
NMIBC	92%	86%	99%
MIBC	92%	86%	99%

GALEAS™ Bladder 於血尿篩查的應用

每年，數以萬計的血尿患者需要接受侵入性膀胱鏡檢查，但僅有約 10% 被診斷為膀胱癌。GALEAS™ Bladder 提供一種非侵入性的分子篩查方案，能夠減少不必要的檢查及相關費用，同時提供快速而準確的結果。

GALEAS™ Bladder 如何支持診斷？

報告

• 陽性/陰性報告會發送給泌尿科醫生
• 提供所識別的體細胞變異的詳細信息

參考文獻

1.  Zhu, C. Z., Ting, H. N., Ng, K. H., & Ong, T. A. (2019). A review on the accuracy of bladder cancer detection methods. Journal of cancer, 10(17), 4038. Full article

2. Alimi, Q., Hascoet, J., Manunta, A., Kammerer‐Jacquet, S. F., Verhoest, G., Brochard, C., … & Peyronnet, B. (2018). Reliability of urinary cytology and cystoscopy for the screening and diagnosis of bladder cancer in patients with neurogenic bladder: a systematic review. Neurourology and Urodynamics, 37(3), 916-925. Full article

3. Ward et al. BJU Int. 2019, Targeted deep sequencing of urothelial bladder cancers and associated urinary DNA: a 23-gene panel with utility for non-invasive diagnosis and risk stratification

3. Ward DG, Gordon NS, Boucher RH, et al. Targeted deep sequencing of urothelial bladder cancers and associated urinary DNA: a 23-gene panel with utility for non-invasive diagnosis and risk stratification. BJU Int. 2019;124(3):532-544. doi:10.1111/BJU.14808. Full article